# Elusys Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elusys-therapeutics

- Industry: Biotechnology
- Headquarters: Parsippany, US
- Website: www.elusys.com
- Total disclosed funding: $43M
- Latest round: Series E (Jan 23, 2007)
- Investors on record: 6

## About

Elusys Therapeutics, Inc. focuses on developing and commercializing medical countermeasures to combat anthrax exposure, providing critical therapeutic solutions to enhance biosecurity on a national and international scale.Founded in 1998 and headquartered in Parsippany, US, Elusys Therapeutics specializes in medical countermeasures. The company has undergone strategic developments and was acquired by Heat Biologics, Inc. in December 2021, with the deal expected to close in early 2022. Elizabeth Posillico serves as CEO. Elusys has completed 5 funding rounds, raising a total of USD 5.00 mn, with the latest being a Series E round led by Essex Woodlands and Invesco Private Capital. Their current company valuation is USD 82.589 mn.Elusys Therapeutics specializes in the development and commercialization of medical countermeasures aimed at mitigating the effects of anthrax exposure. Its flagship product, ANTHIM® (obiltoxaximab), has been commercially available in the United States since 2016 and in Canada since 2020. ANTHIM® is included in the Strategic National Stockpile and is marketed primarily to government agencies such as BARDA, NIAID, and the DoD, as well as international clients like the Public Health Agency of Canada.Elusys Therapeutics has secured over USD 450 mn in procurement and development contracts, primarily through collaborations with governmental health organizations. The revenue structure mainly involves government contracts for bulk purchases of ANTHIM® as part of national preparedness initiatives, focusing on large-scale procurement by federal and state health agencies.Elusys Therapeutics aims to utilize its recent funding to expand its product offerings and enhance its market reach. The company is exploring new product designs and potential launches, though specific details and dates are not yet disclosed. With the anticipated closing of the acquisition by Heat Biologics, Elusys may broaden its market presence and develop additional strategic partnerships to further its growth initiatives.

## Funding rounds

- Series E, Jan 23, 2007, $5M — Essex Woodlands, Invesco
- Series D, Jul 13, 2006, $11M — Crescendo Ventures, Essex Woodlands, Invesco, MedImmune Ventures
- Series D, Aug 3, 2004, $10M — Crescendo Ventures, Essex Woodlands, Invesco, Calvert Street Capital Partners, Eagle Advisors
- Series C, Jul 16, 2001, $17M — Crescendo Ventures, Essex Woodlands, Invesco, Calvert Street Capital Partners, Eagle Advisors

## Investors

- Crescendo Ventures (https://capitalatlas.ai/funds/crescendo-ventures) — Series C, Series D
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series D, Series E
- Invesco (https://capitalatlas.ai/funds/invesco) — Series C, Series D, Series E
- Calvert Street Capital Partners — Series C, Series D
- Eagle Advisors — Series C, Series D
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series D